Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Merck & Company, Inc. (MRK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 10, 2014.
Market data for MRK model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
|% Held by Insiders||0.27%|
|% Held by Institutions||70.50%|
|EPS (last reported FY)||$5.19|
|EPS (last reported Q)||$1.16|
|EPS, estimated (last reported Q)||$1.14|
|Total revenues||$47 B|
|Net income||$10 B|